https://www.prognyx.com/2026-09-12weekly1.0 https://www.prognyx.com/fr2026-09-12weekly0.9 https://www.prognyx.com/blog2026-09-12daily0.9 https://www.prognyx.com/blog/index.fr2026-09-12daily0.8 https://www.prognyx.com/blog/page/22026-09-12weekly0.5 https://www.prognyx.com/blog/page/2.fr2026-09-12weekly0.5 https://www.prognyx.com/about2026-09-12monthly0.8 https://www.prognyx.com/fr/about2026-09-12monthly0.7 https://www.prognyx.com/alternatives/citeline2026-09-12monthly0.7 https://www.prognyx.com/fr/alternatives/citeline2026-09-12monthly0.6 https://www.prognyx.com/alternatives/globaldata2026-09-12monthly0.7 https://www.prognyx.com/fr/alternatives/globaldata2026-09-12monthly0.6 https://www.prognyx.com/alternatives/beacon2026-09-12monthly0.7 https://www.prognyx.com/fr/alternatives/beacon2026-09-12monthly0.6 https://www.prognyx.com/alternatives/in-house-ci-analyst2026-09-12monthly0.7 https://www.prognyx.com/fr/alternatives/in-house-ci-analyst2026-09-12monthly0.6 https://www.prognyx.com/alternatives/cortellis2026-09-12monthly0.7 https://www.prognyx.com/fr/alternatives/cortellis2026-09-12monthly0.6 https://www.prognyx.com/alternatives/alphasense2026-09-12monthly0.7 https://www.prognyx.com/fr/alternatives/alphasense2026-09-12monthly0.6 https://www.prognyx.com/competitive-intelligence-tools-small-biotech2026-09-12monthly0.8 https://www.prognyx.com/fr/competitive-intelligence-tools-small-biotech2026-09-12monthly0.7 https://www.prognyx.com/landscapes/pd1-vegf-bispecifics2026-09-12weekly0.8 https://www.prognyx.com/fr/landscapes/pd1-vegf-bispecifics2026-09-12weekly0.7 https://www.prognyx.com/landscapes/kras-g12c2026-09-12weekly0.8 https://www.prognyx.com/fr/landscapes/kras-g12c2026-09-12weekly0.7 https://www.prognyx.com/methodology2026-09-12monthly0.8 https://www.prognyx.com/fr/methodology2026-09-12monthly0.7 https://www.prognyx.com/newsletter2026-09-12monthly0.7 https://www.prognyx.com/fr/newsletter2026-09-12monthly0.6 https://www.prognyx.com/privacy2026-09-12yearly0.3 https://www.prognyx.com/fr/privacy2026-09-12yearly0.2 https://www.prognyx.com/sample-brief2026-09-12monthly0.8 https://www.prognyx.com/fr/sample-brief2026-09-12monthly0.7 https://www.prognyx.com/oncology-competitive-intelligence2026-09-12monthly0.9 https://www.prognyx.com/fr/oncology-competitive-intelligence2026-09-12monthly0.8 https://www.prognyx.com/terms2026-09-12yearly0.3 https://www.prognyx.com/fr/terms2026-09-12yearly0.2 https://www.prognyx.com/what-is-prognyx2026-09-12monthly0.8 https://www.prognyx.com/fr/what-is-prognyx2026-09-12monthly0.7 https://www.prognyx.com/blog/beone-s-cll-phase-3-puts-sonrotoclax-against-venetoclax-plus-acalabrutinib2026-09-12monthly0.7 https://www.prognyx.com/blog/beone-s-cll-phase-3-puts-sonrotoclax-against-venetoclax-plus-acalabrutinib.fr2026-09-12monthly0.7 https://www.prognyx.com/blog/zipalertinib-s-rezilient3-hits-its-pfs-endpoint-in-first-line-egfr-exon-20-lung2026-09-10monthly0.7 https://www.prognyx.com/blog/zipalertinib-s-rezilient3-hits-its-pfs-endpoint-in-first-line-egfr-exon-20-lung.fr2026-09-10monthly0.7 https://www.prognyx.com/blog/per-endpoints-news-bristol-myers-squibb-claims-phase-2-success-for-a-gprc5d-dire2026-09-09monthly0.7 https://www.prognyx.com/blog/per-endpoints-news-bristol-myers-squibb-claims-phase-2-success-for-a-gprc5d-dire.fr2026-09-09monthly0.7 https://www.prognyx.com/blog/astrazeneca-reports-durvalumab-tarlatamab-maintenance-improves-survival-in-first2026-09-08monthly0.7 https://www.prognyx.com/blog/astrazeneca-reports-durvalumab-tarlatamab-maintenance-improves-survival-in-first.fr2026-09-08monthly0.7 https://www.prognyx.com/blog/per-endpoints-news-novartis-pauses-immunology-and-neuroscience-car-t-studies-aft2026-09-07monthly0.7 https://www.prognyx.com/blog/per-endpoints-news-novartis-pauses-immunology-and-neuroscience-car-t-studies-aft.fr2026-09-07monthly0.7 https://www.prognyx.com/blog/pfizer-licenses-its-terminated-cd228-adc-pf-08046031-to-medicus-pharma-while-kee2026-09-06monthly0.7 https://www.prognyx.com/blog/pfizer-licenses-its-terminated-cd228-adc-pf-08046031-to-medicus-pharma-while-kee.fr2026-09-06monthly0.7 https://www.prognyx.com/blog/fda-grants-accelerated-approval-to-astrazeneca-s-etcamah-camizestrant-an-oral-se2026-09-05monthly0.7 https://www.prognyx.com/blog/fda-grants-accelerated-approval-to-astrazeneca-s-etcamah-camizestrant-an-oral-se.fr2026-09-05monthly0.7 https://www.prognyx.com/blog/abbvie-s-etentamig-cuts-progression-or-death-risk-60-in-phase-3-cervino-myeloma2026-09-04monthly0.7 https://www.prognyx.com/blog/abbvie-s-etentamig-cuts-progression-or-death-risk-60-in-phase-3-cervino-myeloma.fr2026-09-04monthly0.7 https://www.prognyx.com/blog/summit-files-harmoni-2-os-positive-update-for-ivonescimab2026-09-03monthly0.7 https://www.prognyx.com/blog/summit-files-harmoni-2-os-positive-update-for-ivonescimab.fr2026-09-03monthly0.7 https://www.prognyx.com/blog/per-endpoints-a-cber-director-overruled-reviewers-to-clear-replimune-s-tudriqev2026-09-02monthly0.7 https://www.prognyx.com/blog/per-endpoints-a-cber-director-overruled-reviewers-to-clear-replimune-s-tudriqev.fr2026-09-02monthly0.7 https://www.prognyx.com/blog/enhertu-plus-pertuzumab-wins-eu-first-line-her2-positive-metastatic-breast-cance2026-09-01monthly0.7 https://www.prognyx.com/blog/enhertu-plus-pertuzumab-wins-eu-first-line-her2-positive-metastatic-breast-cance.fr2026-09-01monthly0.7 https://www.prognyx.com/blog/pmv-announces-31-august-rezatapopt-ovarian-update-for-pynnacle2026-08-31monthly0.7 https://www.prognyx.com/blog/pmv-announces-31-august-rezatapopt-ovarian-update-for-pynnacle.fr2026-08-31monthly0.7 https://www.prognyx.com/blog/ipsen-closes-the-kartos-acquisition-and-inherits-one-recruiting-phase-3-with-a-32026-08-21monthly0.7 https://www.prognyx.com/blog/ipsen-closes-the-kartos-acquisition-and-inherits-one-recruiting-phase-3-with-a-3.fr2026-08-21monthly0.7 https://www.prognyx.com/blog/merck-and-moderna-declare-a-phase-3-melanoma-win-for-intismeran-autogene-per-end2026-08-19monthly0.7 https://www.prognyx.com/blog/merck-and-moderna-declare-a-phase-3-melanoma-win-for-intismeran-autogene-per-end.fr2026-08-19monthly0.7 https://www.prognyx.com/blog/iberdomide-zenbexus-wins-accelerated-approval-in-relapsed-myeloma-and-five-spons2026-08-14monthly0.7 https://www.prognyx.com/blog/iberdomide-zenbexus-wins-accelerated-approval-in-relapsed-myeloma-and-five-spons.fr2026-08-14monthly0.7 https://www.prognyx.com/blog/zipalertinib-plus-chemo-meets-its-pfs-endpoint-at-interim-in-first-line-egfr-exo2026-08-13monthly0.7 https://www.prognyx.com/blog/zipalertinib-plus-chemo-meets-its-pfs-endpoint-at-interim-in-first-line-egfr-exo.fr2026-08-13monthly0.7 https://www.prognyx.com/blog/endpoints-reports-the-fda-rejected-itm-s-neuroendocrine-tumor-radiopharmaceutica2026-08-12monthly0.7 https://www.prognyx.com/blog/endpoints-reports-the-fda-rejected-itm-s-neuroendocrine-tumor-radiopharmaceutica.fr2026-08-12monthly0.7 https://www.prognyx.com/blog/divesiran-hits-88-versus-19-in-phase-2-polycythemia-vera-silence-takes-quarterly2026-08-11monthly0.7 https://www.prognyx.com/blog/divesiran-hits-88-versus-19-in-phase-2-polycythemia-vera-silence-takes-quarterly.fr2026-08-11monthly0.7 https://www.prognyx.com/blog/galleri-s-randomized-endpoint-came-back-at-1-03-and-an-fda-advisory-committee-is2026-08-07monthly0.7 https://www.prognyx.com/blog/galleri-s-randomized-endpoint-came-back-at-1-03-and-an-fda-advisory-committee-is.fr2026-08-07monthly0.7 https://www.prognyx.com/blog/two-phase-3s-target-low-intensity-follicular-lymphoma-standards-surovatamig-vs-r2026-08-06monthly0.7 https://www.prognyx.com/blog/two-phase-3s-target-low-intensity-follicular-lymphoma-standards-surovatamig-vs-r.fr2026-08-06monthly0.7 https://www.prognyx.com/blog/nurix-enrols-the-first-patient-in-a-phase-3-designed-to-demonstrate-bexobrutideg2026-08-05monthly0.7 https://www.prognyx.com/blog/nurix-enrols-the-first-patient-in-a-phase-3-designed-to-demonstrate-bexobrutideg.fr2026-08-05monthly0.7 https://www.prognyx.com/blog/pluvicto-approved-with-an-arpi-in-psma-positive-mhspc-radioligand-therapy-arrive2026-08-04monthly0.7 https://www.prognyx.com/blog/pluvicto-approved-with-an-arpi-in-psma-positive-mhspc-radioligand-therapy-arrive.fr2026-08-04monthly0.7 https://www.prognyx.com/blog/selinexor-s-tp53-wild-type-bet-misses-xport-ec-042-returns-a-hazard-ratio-of-0-72026-08-01monthly0.7 https://www.prognyx.com/blog/selinexor-s-tp53-wild-type-bet-misses-xport-ec-042-returns-a-hazard-ratio-of-0-7.fr2026-08-01monthly0.7 https://www.prognyx.com/blog/j-j-s-reported-785m-upfront-for-sail-comes-with-a-2-58b-option-on-in-vivo-car-t2026-07-30monthly0.7 https://www.prognyx.com/blog/j-j-s-reported-785m-upfront-for-sail-comes-with-a-2-58b-option-on-in-vivo-car-t.fr2026-07-30monthly0.7 https://www.prognyx.com/blog/replimune-s-own-filing-shows-the-rp1-melanoma-pivotal-was-a-single-arm-cohort-th2026-07-29monthly0.7 https://www.prognyx.com/blog/replimune-s-own-filing-shows-the-rp1-melanoma-pivotal-was-a-single-arm-cohort-th.fr2026-07-29monthly0.7 https://www.prognyx.com/blog/astrazeneca-s-cldn18-2-adc-won-a-late-stage-trial-with-a-caveat-and-the-caveat-i2026-07-28monthly0.7 https://www.prognyx.com/blog/astrazeneca-s-cldn18-2-adc-won-a-late-stage-trial-with-a-caveat-and-the-caveat-i.fr2026-07-28monthly0.7 https://www.prognyx.com/blog/daraxonrasib-reportedly-reaches-fda-review-in-pretreated-pancreatic-cancer-an-or2026-07-24monthly0.7 https://www.prognyx.com/blog/daraxonrasib-reportedly-reaches-fda-review-in-pretreated-pancreatic-cancer-an-or.fr2026-07-24monthly0.7 https://www.prognyx.com/blog/ivonescimab-s-western-os-hazard-ratio-falls-to-0-76-summit-hasn-t-yet-disclosed2026-07-23monthly0.7 https://www.prognyx.com/blog/ivonescimab-s-western-os-hazard-ratio-falls-to-0-76-summit-hasn-t-yet-disclosed.fr2026-07-23monthly0.7 https://www.prognyx.com/blog/astrazeneca-s-nct06764875-pits-a-rilvegostomig-enhertu-regimen-against-the-pembr2026-06-17monthly0.7 https://www.prognyx.com/blog/astrazeneca-s-nct06764875-pits-a-rilvegostomig-enhertu-regimen-against-the-pembr.fr2026-06-17monthly0.7 https://www.prognyx.com/blog/elicio-s-kras-vaccine-missed-its-phase-2-primary-endpoint-it-s-staking-a-phase-32026-06-15monthly0.7 https://www.prognyx.com/blog/elicio-s-kras-vaccine-missed-its-phase-2-primary-endpoint-it-s-staking-a-phase-3.fr2026-06-15monthly0.7 https://www.prognyx.com/blog/spectrum-terminates-its-648-patient-poziotinib-exon-20-phase-2-a-business-call-n2026-06-15monthly0.7 https://www.prognyx.com/blog/spectrum-terminates-its-648-patient-poziotinib-exon-20-phase-2-a-business-call-n.fr2026-06-15monthly0.7